AI-Native Scoping Reviews & Evidence Mapping

Cannabis legalization is not a single public-health story: the strongest signal emerges after commercialization, where higher use, ED visits, hyperemesis, pediatric exposures, psychosis-related harms, and vulnerable-population risks become more visible. The full SAIMSARA evidence map is worth reading because it separates legalization, retail expansion, potency, packaging, taxation, risk perception, and clinical-risk groups across 175 references and 533 original studies.

This review maps 995 original studies and 26.6 million participants comparing apixaban and rivaroxaban across AF, VTE, CKD, cirrhosis, cancer, elderly, and other high-risk populations. It delivers a clear human- and machine-ready signal: apixaban shows a more favorable bleeding profile, while rivaroxaban remains relevant in selected adherence, cost, VTE, and orthopedic contexts.

Therapeutic drug monitoring of antibiotics turns dosing from guesswork into measurable precision, especially in critically ill, pediatric, burn, ECMO, renal-replacement, and other high-risk patients where standard regimens often miss PK/PD targets. This SAIMSARA evidence map is worth reading because it separates practical dosing signals from implementation noise, mapping β-lactams, vancomycin, aminoglycosides, toxicity thresholds, assay reliability, digital dosing tools, and stewardship workflows across 394 original studies.

Snuffbox AVF emerges as a clinically credible distal-first hemodialysis access strategy, offering patency broadly comparable to wrist radiocephalic fistulas while preserving future access options. The full SAIMSARA evidence map is worth reading because it separates durable signals from selection-dependent outcomes, complications, reintervention needs, vessel-diameter thresholds, and long-term uncertainty across the available snuffbox fistula literature.

Cannabis is no longer a peripheral cardiovascular question: this evidence map shows repeated risk signals for MI, stroke, arrhythmias, perioperative events, vascular stiffness, and acute THC-driven hemodynamic stress, while also separating mixed or null findings for hypertension and atrial fibrillation. The full SAIMSARA evidence map is worth reading because it organizes 259 original studies into clinically usable risk patterns across daily use, CUD, medical cannabis, CBD, synthetic cannabinoids, pregnancy, young ACS patients, surgery, and vulnerable cardiovascular populations.

AI clinical scribes can reduce documentation burden, but this evidence map shows why they are not yet safe as autonomous note-writers: hallucinations, omissions, acoustic failures, EHR friction, consent gaps, and medicolegal uncertainty remain central limitations. The full SAIMSARA evidence map gives a structured, reference-linked view of where ambient AI documentation works, where it fails, and what clinicians, vendors, and health systems must verify before scaling it.

Medical machine translation may look fluent, but this review shows where it still breaks: semantic precision, cultural nuance, audience adaptation, and high-stakes clinical reliability. The full read is worth it because it separates the real strengths of MT in constrained tasks from the specific failure modes that still make expert human oversight essential.

This review shows that the strongest medication signal in AAA is not true aneurysm-shrinking therapy, but better survival: statins and antiplatelet treatment repeatedly track with lower long-term mortality, while most putative growth-modifying drugs still rest on mixed or observational evidence. It maps where medical AAA care is already actionable today, where metformin and other candidates remain uncertain, and which pharmacologic strategies may genuinely change aneurysm biology rather than just cardiovascular risk.